Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18609954 | MULTI-LAYERED POLYMER FILM FOR SUSTAINED RELEASE OF AGENTS | March 2024 | February 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18606877 | Pharmaceutical Complex for Radioprotection, Preparation Method, and Applications thereof | March 2024 | May 2025 | Abandon | 14 | 2 | 1 | No | No |
| 18602676 | ADIPOSE TISSUE MATRICES | March 2024 | April 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18581460 | Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine | February 2024 | April 2025 | Allow | 13 | 1 | 0 | No | No |
| 18411935 | Method of Preventing and Treating COVID-19 Infection | January 2024 | April 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18405543 | Compacted Hemostatic Cellulosic Aggregates | January 2024 | July 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18506204 | ACTIVE AGENT-CONTAINING MATRIX PARTICLES AND PROCESSES FOR MAKING SAME | November 2023 | January 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18491407 | C-Met Modulator Pharmaceutical Compositions | October 2023 | January 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18243740 | RECTAL ADMINISTRATION OF ROFLUMILAST FOR THE TREATMENT OF CROHN'S DISEASE | September 2023 | May 2024 | Abandon | 8 | 2 | 0 | No | No |
| 18454612 | METHODS OF USING EHMT2 INHIBITORS IN TREATING OR PREVENTING BLOOD DISORDERS | August 2023 | January 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18343324 | PHARMACEUTICAL COMPOSITIONS OF PROTAC COMPOUNDS AND USES THEREOF | June 2023 | April 2025 | Allow | 22 | 3 | 1 | Yes | No |
| 18336288 | USE OF CANNABINOIDS IN TREATING ANTI-DEPRESSANT-INDUCED FEMALE SEXUAL DYSFUNCTION | June 2023 | January 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18304306 | USE OF VERAPAMIL FOR THE TREATMENT OF SARS-COV-2 INDUCED COVID-19 | April 2023 | January 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18303082 | VISCOSITY-REDUCING EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | April 2023 | November 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18126901 | TOPICAL THERAPEUTIC FORMULATIONS | March 2023 | December 2024 | Allow | 21 | 2 | 0 | No | No |
| 18113963 | COMPOSITIONS AND METHODS FOR TREATING CANKER SORES | February 2023 | April 2025 | Allow | 26 | 3 | 0 | No | No |
| 18095478 | HEAT STABLE HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USE | January 2023 | November 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18003644 | METHODS OF TREATMENT FOR A KIDNEY DISEASE | December 2022 | July 2025 | Allow | 30 | 0 | 0 | No | No |
| 18007787 | PLASMA KALLIKREIN INHIBITORS | December 2022 | June 2025 | Allow | 30 | 0 | 0 | No | No |
| 17926284 | A TOPICAL ANTIMICROBIAL COMPOSITION | November 2022 | August 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 17921426 | COMPOSITION FOR TREATING AND/OR PREVENTING VESTIBULODYNIA | October 2022 | March 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 17974231 | COMPOSITIONS AND FORMULATIONS INCLUDING CABAZITAXEL AND HUMAN SERUM ALBUMIN | October 2022 | June 2024 | Allow | 20 | 1 | 0 | No | No |
| 17961961 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | October 2022 | November 2024 | Allow | 26 | 3 | 0 | Yes | No |
| 17953407 | BIORESORBABLE METAL ALLOY AND IMPLANTS | September 2022 | August 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 17933071 | VISCOSITY-REDUCING EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | September 2022 | January 2023 | Allow | 4 | 1 | 0 | No | No |
| 17943691 | Dihydromyricetin Hot Melt Extrusion Formulations and Methods for Forming Them | September 2022 | February 2025 | Allow | 29 | 2 | 1 | No | No |
| 17939348 | NICOTINE PARTICLES | September 2022 | March 2024 | Allow | 18 | 1 | 0 | No | No |
| 17814567 | THERMO-KINETIC MIXING FOR PHARMACEUTICAL APPLICATIONS | July 2022 | February 2024 | Allow | 19 | 1 | 0 | No | No |
| 17724078 | CHRYSEOBACTERIUM INSECT INHIBITORY MICROBIAL COMPOSITIONS AND METHODS OF MAKING AND USING | April 2022 | September 2024 | Allow | 29 | 3 | 0 | Yes | No |
| 17717922 | MODIFIED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING DEFERIPRONE | April 2022 | February 2024 | Allow | 22 | 3 | 1 | Yes | No |
| 17717913 | MODIFIED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING DEFERIPRONE | April 2022 | February 2024 | Allow | 22 | 3 | 1 | Yes | No |
| 17702731 | METHOD AND DEVICE TO TRAP ACARIDS | March 2022 | January 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17761652 | METHOD FOR MANUFACTURING DISPERSION OF ULTRAFINE PARTICLES OF POORLY SOLUBLE SUBSTANCE | March 2022 | April 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17694571 | DIHYDROMYRICETIN NANOEMULSION FORMULATIONS AND METHODS FOR FORMING THEM | March 2022 | June 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17638821 | Temperature-Sensitive Hydrogel Composition for Preventing Tissue Adhesion, and Preparation Method Therefor | February 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17597974 | Poly(Beta-Thioester) Polymers and Polymeric Nanoparticles | January 2022 | March 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17631637 | LIQUID ORAL CARE COMPOSITION | January 2022 | March 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17581591 | EXTRACELLULAR MATRIX (ECM) HYDROGEL AS A SUBMUCOSAL FLUID CUSHION | January 2022 | April 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17628830 | SUBSTITUTED N-PHENYL-N-AMINOUARCILS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | January 2022 | February 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17578669 | TOPICAL COMPOSITIONS AND METHODS OF USE THEREOF | January 2022 | October 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17597604 | PARTICLES, PHARMACEUTICAL COMPOSITION, AND METHOD FOR PRODUCING PARTICLES | January 2022 | April 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17625408 | CAPSULE FOR COSMETICS | January 2022 | December 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17570253 | FORMULATIONS OF L-ORNITHINE PHENYLACETATE | January 2022 | October 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17568452 | METHODS OF PREVENTING AND TREATING COVID-19 INFECTION | January 2022 | April 2023 | Abandon | 16 | 2 | 0 | No | No |
| 17559027 | LIP PRODUCT FORMULATION, APPLICATOR, AND METHOD FOR MAKING SAME | December 2021 | June 2023 | Allow | 18 | 0 | 0 | No | No |
| 17559372 | Compacted Hemostatic Cellulosic Aggregates | December 2021 | September 2023 | Allow | 21 | 1 | 1 | No | No |
| 17559453 | FORMULATIONS OF L-ORNITHINE PHENYLACETATE | December 2021 | September 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17619627 | PLANT VITALIZING AGENT CONTAINING EXOGENOUS ELICITOR AND ENDOGENOUS ELICITOR AND USE THEREOF | December 2021 | April 2025 | Allow | 40 | 2 | 0 | No | No |
| 17457176 | ANTIBIOFILM FORMULATIONS | December 2021 | December 2024 | Allow | 36 | 1 | 1 | No | No |
| 17531430 | CANNABINOID DOSAGE FORMS | November 2021 | October 2024 | Allow | 35 | 3 | 0 | Yes | No |
| 17527581 | NUTRACEUTICAL FORMULATION FOR POLYCYSTIC OVARY SYNDROME | November 2021 | April 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17520787 | NOVEL USE OF SODIUM DICHLOROISOCYANURATE (NaDCC) AND A PHARMACEUTICAL FORMULATION PREPARED THEREFROM | November 2021 | January 2024 | Allow | 26 | 1 | 1 | No | No |
| 17510692 | Finished Fibrous Structures and Methods of Their Use and Preparation | October 2021 | October 2022 | Abandon | 12 | 1 | 0 | No | No |
| 17509478 | GOLD NANO-DELIVERY SYSTEM FOR PAIN AND CANCER THERAPY | October 2021 | December 2023 | Abandon | 26 | 2 | 0 | Yes | No |
| 17510330 | PROCESS FOR THE PREPARATION OF DRUG LOADED MICROPARTICLES | October 2021 | November 2023 | Allow | 25 | 1 | 1 | No | No |
| 17509487 | GOLD NANO-DELIVERY SYSTEM FOR PAIN AND CANCER THERAPY | October 2021 | February 2024 | Abandon | 27 | 2 | 0 | Yes | No |
| 17604858 | TREATMENT OF VASCULAR AND LYMPHATIC DISEASE | October 2021 | February 2024 | Allow | 28 | 1 | 0 | No | No |
| 17505307 | C-Met Modulator Pharmaceutical Compositions | October 2021 | July 2022 | Abandon | 9 | 1 | 0 | No | No |
| 17594360 | HERBICIDAL COMPOUNDS | October 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17499221 | Wound Dressings and Applications Thereof | October 2021 | January 2024 | Allow | 27 | 1 | 1 | No | No |
| 17489071 | METHOD OF ENHANCING THE EFFICACY AND STABILITY OF INGREDIENTS IN SUSPENSIONS | September 2021 | December 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17593701 | FUNGICIDE FORMULATIONS WITH REDUCED CRYSTAL GROWTH | September 2021 | May 2025 | Allow | 44 | 2 | 1 | No | No |
| 17480616 | CHEMICALS WHICH ALTER THE PRODUCTION OF METABOLITES IN CULTIVATED PLANTS | September 2021 | November 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17474816 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES | September 2021 | November 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17472162 | Composition For Enhancing Protein Strength | September 2021 | January 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17471518 | EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | September 2021 | June 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17408111 | ALL-IN-ONE FIXED-DOSE COMBINATION FOR TREATING HELICOBACTER PYLORI INFECTION | August 2021 | November 2023 | Allow | 27 | 2 | 1 | No | No |
| 17406025 | EPIGENETIC MODIFICATION OF FUNGI AND USES THEREOF | August 2021 | September 2024 | Allow | 37 | 1 | 1 | Yes | No |
| 17444809 | MATERIALS AND METHODS FOR STOPPING RESPIRATORY VIRUS INFECTIONS | August 2021 | December 2023 | Abandon | 28 | 1 | 1 | No | No |
| 17381294 | METHOD FOR REDUCING SKIN SENSITIZATION OF AN ASENAPINE-CONTAINING PATCH | July 2021 | November 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17381705 | Sorafenib particles and uses thereof | July 2021 | July 2023 | Abandon | 24 | 2 | 1 | No | No |
| 17305851 | MULTI-LAYERED POLYMER FILM FOR SUSTAINED RELEASE OF AGENTS | July 2021 | December 2023 | Allow | 29 | 2 | 0 | Yes | No |
| 17375814 | METHOD FOR PREPARING A LIPOSOMAL COMPOSITION COMPRISING LATANOPROST, AND THE PHARMACOLOGICALLY ACTIVE LIPOSOMAL COMPOSITION FOR OPHTHALMOTHERAPY PREPARED BY THIS METHOD | July 2021 | June 2022 | Allow | 11 | 2 | 0 | No | No |
| 17373544 | SYSTEMS AND METHODS FOR USE OF CHLORINE DIOXIDE IN CULTIVATION AND POST-HARVEST APPLICATIONS | July 2021 | February 2025 | Allow | 43 | 4 | 1 | Yes | No |
| 17351453 | ANTIMICROBIAL COATINGS FOR MEDICAL IMPLEMENTS AND MEDICAL DEVICES | June 2021 | August 2023 | Allow | 25 | 1 | 1 | No | No |
| 17350520 | METHODS OF PREVENTING AND TREATING COVID-19 INFECTION | June 2021 | October 2023 | Allow | 28 | 2 | 0 | No | No |
| 17346867 | COMPOSITIONS AND METHODS TO REDUCE DICAMBA VOLATILITY AND PROVIDE PLANT ESSENTIAL NUTRIENTS | June 2021 | April 2024 | Allow | 34 | 4 | 1 | No | Yes |
| 17346872 | METHOD FOR PRODUCING A FIBRIN-BASED BIOARTIFICIAL, PRIMARILY ACELLULAR CONSTRUCT, AND THE CONSTRUCT ITSELF | June 2021 | August 2024 | Allow | 38 | 3 | 1 | No | No |
| 17342859 | PHARMACEUTICAL FORMULATION CONTAINING GLYCOPYRROLATE AND INDACATEROL MALEATE | June 2021 | October 2022 | Abandon | 16 | 2 | 1 | No | No |
| 17341213 | COATED DRUG COMPOSITIONS AND METHODS OF PREPARING THE SAME | June 2021 | April 2024 | Allow | 34 | 2 | 1 | No | No |
| 17332098 | METHODS AND COMPOSITIONS FOR TREATING SEPSIS | May 2021 | April 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17327729 | STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF | May 2021 | June 2024 | Allow | 37 | 3 | 1 | No | No |
| 17294820 | PARAQUAT FORMULATION | May 2021 | March 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17242612 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | April 2021 | July 2023 | Abandon | 26 | 1 | 1 | Yes | No |
| 17289711 | TREATMENT OF EXPOSURE TO CHLORINE GAS WITH SCOPOLAMINE | April 2021 | August 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17234112 | FORMULATION OF CALCIUM CHANNEL BLOCKERS FOR TREATMENT OF SARS-COV-2 INDUCED COVID-19 AND OTHER RESPIRATORY VIRUSES THROUGH PULMONARY DELIVERY | April 2021 | May 2024 | Abandon | 37 | 3 | 0 | No | No |
| 17221532 | MEK1/2 INHIBITOR-LOADED MICROPARTICLE FORMULATION | April 2021 | May 2024 | Abandon | 37 | 3 | 1 | Yes | No |
| 17278291 | SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS | March 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17197204 | ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLES | March 2021 | February 2025 | Allow | 47 | 5 | 0 | No | No |
| 17180917 | COMPOSITION FOR SUBMUCOSAL INJECTION AND PREPARATION METHOD THEREOF | February 2021 | March 2023 | Allow | 25 | 0 | 1 | No | No |
| 17165002 | USE OF CANNABINOIDS IN TREATING ANTI-DEPRESSANT-INDUCED FEMALE SEXUAL DYSFUNCTION | February 2021 | March 2023 | Allow | 25 | 4 | 0 | Yes | Yes |
| 17163119 | Ophthalmic Formulations and Uses Thereof | January 2021 | March 2024 | Abandon | 38 | 2 | 1 | Yes | Yes |
| 17262902 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | January 2021 | November 2024 | Allow | 46 | 3 | 0 | Yes | No |
| 17148262 | TREATMENT OF VOMITING AND NAUSEA WITH MINIMUM DOSE OF OLANZAPINE | January 2021 | November 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 17138507 | Thin Emulsion Base for Cosmetics | December 2020 | August 2023 | Allow | 31 | 2 | 0 | No | No |
| 17126715 | METHODS OF TREATING COVID-19 INFECTION | December 2020 | June 2021 | Allow | 6 | 2 | 0 | Yes | No |
| 17104081 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | November 2020 | February 2024 | Allow | 39 | 0 | 1 | No | No |
| 16953674 | METHODS OF PREVENTING AND TREATING COVID-19 INFECTION | November 2020 | August 2022 | Abandon | 21 | 2 | 1 | No | No |
| 16952789 | METHODS FOR PREVENTION AND TREATMENT OF PRESSURE ULCERS CAUSED BY ISCHEMIA USING CONTACT VASODILATORS | November 2020 | August 2023 | Abandon | 33 | 5 | 1 | Yes | No |
| 17072207 | ADIPOSE TISSUE PRODUCTS AND METHODS OF PRODUCTION | October 2020 | August 2024 | Abandon | 46 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PALLAY, MICHAEL B.
With a 15.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PALLAY, MICHAEL B works in Art Unit 1617 and has examined 770 patent applications in our dataset. With an allowance rate of 53.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner PALLAY, MICHAEL B's allowance rate of 53.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PALLAY, MICHAEL B receive 2.27 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by PALLAY, MICHAEL B is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +37.7% benefit to allowance rate for applications examined by PALLAY, MICHAEL B. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.0% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 30.9% of cases where such amendments are filed. This entry rate is in the 37% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 16.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 23% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 58.7% of appeals filed. This is in the 28% percentile among all examiners. Of these withdrawals, 59.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 71.2% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 57% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.3% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.